Updates are available Correction dated 2024-08-26
Click to view Correction: https://doi.org/10.1038/s41433-024-03309-5
-
Authors
Wijesingha, Naomi https://orcid.org/0000-0003-0206-1061
Kotecha, Aachal
Margaron, Philippe
Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 7 June 2024
Accepted: 21 June 2024
First Online: 10 July 2024
Change Date: 26 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-024-03309-5
Competing interests
: Naomi Wijesingha declares no conflicts of interest. Aachal Kotecha is an employee of Roche Products Ltd. Philippe Margaron is an employee of F. Hoffmann-La Roche Ltd. Sobha Sivaprasad reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Nova Nordisk, Novartis, Ocular Therapeutics, OcuTerra, Optos, Roche, Sanofi, and Stealth Biotherapeutics, and is Editor in Chief of Eye .
